PRE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

38.30M

+264.76%

0.040

-103.1%

45.90M

+165.13%

0.240

-130%

51.20M

+189.59%

0.360

-138.3%

Estimates Revision

The market is revising Downward the revenue expectations for Prenetics Global Limited (PRE) for FY2025, with the revenue forecasts being adjusted by -2.42% over the past three months. During the same period, the stock price has changed by 9.10%.

Revenue Estimates for FY2025

Revise Downward

-2.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-14.94%

In Past 3 Month

Stock Price

Go Up

+9.10%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Prenetics Global Ltd (PRE.O) is 14.61, compared to its 5-year average forward P/E of -2.91. For a more detailed relative valuation and DCF analysis to assess Prenetics Global Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.91

Current PE

14.61

Overvalued PE

2.63

Undervalued PE

-8.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

5.68

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

53.26

Undervalued EV/EBITDA

-41.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.30

Current PS

1.38

Overvalued PS

2.22

Undervalued PS

0.37

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PRE News & Events

Events Timeline

No data

News

4.5

2025-12-30Newsfilter

Prenetics Shifts Focus Exclusively to IM8, Projecting FY 2026 Revenue of $180-$200 Million

3.5

2025-12-24Globenewswire

Presearch Sells Out Inaugural NFT Auction, Exceeding 4 Million Tokens

4.5

2025-12-23Globenewswire

Prenetics Completes 83.4% Warrant Exchange, Reducing Future Dilution Risk

People Also Watch

Frequently Asked Questions

What is Prenetics Global Ltd (PRE) stock price today?

The current price of PRE is 15.53 USD — it has decreased -7.28 % in the last trading day.

What is Prenetics Global Ltd (PRE)'s business?

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

What is the price predicton of PRE Stock?

Wall Street analysts forecast PRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Prenetics Global Ltd (PRE)'s revenue for the last quarter?

Prenetics Global Ltd revenue for the last quarter amounts to 23.56M USD, increased 567.66 % YoY.

What is Prenetics Global Ltd (PRE)'s earnings per share (EPS) for the last quarter?

Prenetics Global Ltd. EPS for the last quarter amounts to -0.53 USD, decreased -36.90 % YoY.

What changes have occurred in the market's expectations for Prenetics Global Ltd (PRE)'s fundamentals?

How many employees does Prenetics Global Ltd (PRE). have?

Prenetics Global Ltd (PRE) has 285 emplpoyees as of January 10 2026.

What is Prenetics Global Ltd (PRE) market cap?

Today PRE has the market capitalization of 261.35M USD.